



SPONTAN® Nasal Spray Shows Positive Real-World Outcomes in Younger Men with Performance-Related Erectile Difficulties

2 February 2026

Highlights

- Independent observational use of SPONTAN® reported positive outcomes in younger men with performance-related erectile difficulties
- All participants reported achieving and maintaining erections sufficient for intercourse following SPONTAN® use
- Younger men with performance-related erectile difficulties represent an underserved segment of the global ED market
- LTR Pharma to evaluate a clinician-initiated clinical study in this patient population

LTR Pharma Limited (ASX:LTP) ("LTR Pharma" or "the Company") is pleased to announce that a small, independent observational case series has reported positive real-world use of its intranasal erectile dysfunction product, SPONTAN®, in men experiencing situational erectile difficulties associated with sexual performance anxiety.

The observations involved five physically healthy men aged 20–30 years who self-identified as experiencing sexual performance anxiety. All participants reported normal erectile function during masturbation but intermittent difficulty maintaining erections during partnered sexual activity, which they attributed to performance anxiety.

SPONTAN nasal spray was used 10–20 minutes prior to partnered sexual activity. All five participants reported achieving and maintaining an erection sufficient for intercourse when using SPONTAN. Reported adverse effects were limited to mild-to-moderate, transient nasal discomfort and sneezing, which resolved spontaneously within approximately five minutes. Three participants noted that nasal symptoms diminished with repeated use over a two-week period.

The observations were based on self-reported outcomes and were not conducted as part of a registered or controlled clinical trial. Limitations include the small sample size, absence of a control group, short follow-up period, and reliance on subjective reporting.

Melissa Hadley Barrett, Nurse Practitioner and Sexologist, said:

"Sexual performance anxiety is a common issue in younger men who are otherwise physically healthy. In my clinical experience, the rapid onset associated with SPONTAN may be particularly relevant for men with situational erectile difficulties, where timing and confidence play a significant role. While these observations are preliminary, they highlight an area where further structured clinical investigation is warranted."



Market Context

Sexual performance anxiety is one of the most common male sexual complaints, with published literature suggesting it affects approximately 9–25% of men, particularly younger men without underlying organic erectile dysfunction.¹ The Company believes this population represents a meaningful and underserved segment of the global erectile dysfunction market, where rapid onset and situational use may be particularly relevant.

Next Steps

Based on these preliminary observational findings, LTR Pharma intends to evaluate the potential for a clinician-initiated clinical study in men experiencing sexual performance anxiety or situational erectile difficulties in the coming year. The Company looks forward to informing the market of any material developments and results from future studies as appropriate.

LTR Pharma Executive Chairman, Lee Rodne, said:

"These observations are encouraging and underscore the breadth of patient populations that may benefit from SPONTAN's rapid onset. We look forward to updating the market as this area develops."

¹ Pyke RE. Sexual Performance Anxiety. *Sex Med Rev.* 2020;8(2):183-190. doi:10.1016/j.sxmr.2019.07.001

- ENDS -

This announcement has been approved by the Board of Directors.

About LTR Pharma

LTR Pharma is a commercial-stage pharmaceutical company delivering innovative therapies to address significant unmet medical needs through its proprietary intranasal drug-delivery platform. The Company has successfully commercialised its rapid-acting treatment technology in Australia and is expanding access whilst advancing regulatory pathways in the US and other key markets.

LTR's lead products, **SPONTAN®** and **ROXUS®**, are fast-acting intranasal sprays for the treatment of erectile dysfunction, enabling onset of action in 10 minutes or less. Building on this proven technology, the Company is now advancing **OROFLOW®**, a novel intranasal spray under development for the treatment of Oesophageal Motility Disorders (OMD) – a debilitating group of conditions affecting swallowing function.

Through strategic partnerships, LTR Pharma is expanding its pipeline and global footprint to deliver differentiated, patient-centric treatments that enhance quality of life.



LTR Pharma

LTR Pharma Investor Centre

Stay informed with LTR Pharma's latest announcements and market updates by visiting our [Investor Centre](#) or scan the QR code.



For further information please contact:

Media enquiries
Haley Chartres
haley@hck.digital

Investor enquiries
Peter McLennan
investors@ltrpharma.com

For personal use only